Contrasting CymaBay Therapeutics (CBAY) & Its Peers

CymaBay Therapeutics (NASDAQ: CBAY) is one of 294 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare CymaBay Therapeutics to related businesses based on the strength of its dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Profitability

This table compares CymaBay Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CymaBay Therapeutics N/A -425.44% -122.91%
CymaBay Therapeutics Competitors -5,205.14% -388.45% -43.01%

Earnings and Valuation

This table compares CymaBay Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
CymaBay Therapeutics $4.79 million -$20.29 million -7.62
CymaBay Therapeutics Competitors $473.33 million $171.79 million -7.10

CymaBay Therapeutics’ rivals have higher revenue and earnings than CymaBay Therapeutics. CymaBay Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

CymaBay Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, CymaBay Therapeutics’ rivals have a beta of 6.61, indicating that their average stock price is 561% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for CymaBay Therapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CymaBay Therapeutics 0 0 9 0 3.00
CymaBay Therapeutics Competitors 721 3159 11772 263 2.73

CymaBay Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 73.27%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.62%. Given CymaBay Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe CymaBay Therapeutics is more favorable than its rivals.

Insider and Institutional Ownership

25.9% of CymaBay Therapeutics shares are held by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 15.1% of CymaBay Therapeutics shares are held by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

CymaBay Therapeutics rivals beat CymaBay Therapeutics on 8 of the 12 factors compared.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply